Potential of cancer cell-derived exosomes in clinical application: A review of recent research advances

Clinical Therapeutics

Volumn 36, Issue 6, 2014, Pages 863-872

  Sun, Yu ^a   Liu, Jing ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Cancer; Diagnosis; Exosomes; Therapy

Indexed keywords

BIOLOGICAL MARKER; DNA; DRUG VEHICLE; LIPID; MICRORNA; NUCLEIC ACID; SIGNAL PEPTIDE; TUMOR MARKER;

ANGIOGENESIS; BODY FLUID; CANCER CELL; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER THERAPY; CELL MOTILITY; DRUG DELIVERY SYSTEM; EXOSOME; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; MEDLINE; MEMBRANE VESICLE; METASTASIS; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR CELL; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; STEM CELL NICHE;

BIOMARKERS; EXOSOMES; HUMANS; MICRORNAS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STEM CELL NICHE; TUMOR MICROENVIRONMENT;

EID: 84902846899     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2014.04.018     Document Type: Review

References (59)

1. Corrado C, Raimondo S, Chiesi A, et al. Exosomes as intercellular signaling organelles involved in health and disease: basic science and clinical applications. Int J Mol Sci. 2013;14:5338-5366.
2. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2: 569-579. (Pubitemid 37328732)
3. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell. 1983;33:967-978.
4. Keller S, Ridinger J, Rupp AK, et al. Bodily fluid derived exosomes as a novel template for clinical diagnostics. J Transl Med. 2011;9:86.
5. Zoller M. Tetraspanins: push and pull in suppressing and promoting metastasis. Nat Rev Cancer. 2009;9:40-55.
6. Raimondo F, Morosi L, Chinello C, et al. Advances in membranous vesicle and exosome proteomics improving biological understanding and biomarker discovery. Pro-teomics. 2011;11:709-720.
7. Simona F, Laura S, Simona T, Riccardo A. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics. 2013;13:1581-1594.
8. Valadi H, Ekstrom K, Bossios A, et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007;9: 654-659. (Pubitemid 47214727)
9. Raiborg C, Rusten TE, Stenmark H. Protein sorting into multivesicular endosomes. Curr Opin Cell Biol. 2003;15:446- 455. (Pubitemid 36928047)
10. Lotvall J, Valadi H. Cell to cell signalling by exosomes through esRNA. Cell Adh Migr. 2007;1:156-158.
11. Hannafon BN, Ding WQ. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci. 2013;14:14240-14269.
12. Record M, Subra C, Silvente-Poirot S, et al. Exosomes as intercellular signalosomes and pharmacological effectors. Biochem Pharmacol. 2011;81:1171-1182.
13. Andre F, Schartz NE, Chaput N, et al. Tumor derived exosomes: a new source of tumor rejection antigens. Vaccine. 2002;20(Suppl 4):A28-A31. (Pubitemid 35452633)
14. Dolo V, Adobati E, Canevari S, et al. Membrane vesicles shed into the extracellular medium by human breast carcinoma cells carry tumor-associated surface antigens. Clin Exp Metastasis. 1995;13:277-286.
15. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med. 2012; 18:883-891.
16. Zhuang G, Wu X, Jiang Z, et al. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. EMBO J. 2012;31:3513-3523.
17. Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by micro-vesicles derived from tumour cells. Nature Cell Biol. 2008; 10:619-624. (Pubitemid 351627382)
18. McCready J, Sims JD, Chan D, et al. Secretion of extracellular hsp90alpha by exosomes increases cancer cell motility a role for plasminogen activation. BMC Cancer. 2010;10:294.
19. Zhang HG, Grizzle WE. Exosomes and cancer: a newly described pathway of immune suppression. Clin Cancer Res. 2011;17:959-964.
20. Mu W, Rana S, Zoller M. Host matrix modulation by tumor exosomes promotes motility and invasiveness. Neoplasia. 2013;15:875-887.
21. Christianson HC, Svensson KJ, van Kuppevelt TH, et al. Cancer cell exosomes depend on cell-surface heparin sulfate proteoglycans for their internalization and functional activity. Proc Natl Acad Sci U S A. 2013;110:17380- 17385.
22. O'Brien K, Rani S, Corcoran C, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013;49:1845-1859.
23. Nakasone ES, Askautrud HA, Kees T, et al. Imaging tumor-stroma interactions during chemotherapy reveals contributions of the micro-environment to resistance. Cancer Cell. 2012;21:488-503.
24. Joyce JA, Pollard JW. Microenvir-onmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
25. Suetsugu A, Honma K, Saji S, et al. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. Adv Drug De-liv Rev. 2013;65:383-390.
26. Janowska-Wieczorek A, Wysoczyn-ski M, Kijowski J, et al. Micro-vesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. Int J Cancer. 2005;113:752-760. (Pubitemid 40101256)
27. Luga V, Zhang L, Viloria-Petit AM, et al. Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012;151:1542-1556.
28. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008;10:1470-1476.
29. Hong BS, Cho JH, Kim H, et al. Colorectal cancer cell-derived microvesicles are enriched in cell cycle-related mRNAs that promote proliferation of endothelial cells. BMC Genomics. 2009;10:556.
30. Kucharzewska P, Christianson HC, Welch JE, et al. Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development. Proc Natl Acad Sci U S A. 2013;110:7312-7317.
31. Jung T, Castellana D, Klingbeil P, et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia. 2009;11: 1093-1105.
32. Hood JL, San RS, Wickline SA. Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res. 2011;71:3792-3801.
33. Viaud S, Théry C, Ploix S, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res. 2010;70:1281-1285.
34. Filipazzi P, Burdek M, Villa A, et al. Recent advances on the role of tumor exosomes in immunosuppres-sion and disease progression. Semin Cancer Biol. 2012;22:342-349.
35. Taylor DD, Gercel-Taylor C, Lyons KS, et al. T-cell apoptosis and suppression of T-cell receptor/CD3-ζ by Fas ligand containing membrane vesicles shed from ovarian tumors. Clin Cancer Res. 2003;9:5113-5119 . (Pubitemid 37413559)
36. Wada J, Onishi H, Suzuki H, et al. Surface-bound TGF-beta1 on effusion-derived exosomes participates in maintenance of number and suppressive function of regulatory T-cells in malignant effusions. Anticancer Res. 2010;30: 3747-3457.
37. Clayton A, Al-Taei S, Webber J, et al. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol. 2011;187:676-683.
38. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immuno-suppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457- 471.
39. Yang C, Ruffner MA, Kim SH, Robbins PD, Plasma-derived MHC. class II exosomes from tumor-bearing mice suppress tumor antigen-specific immune responses. Eur J Immunol. 2012;42:1778- 1784.
40. Zech D, Rana S, Buchler MW, Zoller M. Tumor-exosomes and leukocyte activation: an ambivalent crosstalk. Cell Commun Signal. 2012;10:37.
41. Chen T, Guo J, Yang M, et al. Chemokine-containing exosomes are released from heat-stressed tumor cells by lipid raft-dependent pathway and act as efficient tumor vaccine. J Immunol. 2011; 186:2219-2228.
42. Henderson MC, Azorsa DO. The genomic and proteomic content of cancer cell-derived exosomes. Front Oncol. 2012;2:38.
43. Adamczyk KA, Klein-Scory S, Teh-rani MM, et al. Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells. Life Sci. 2011;89:304- 312 .
44. Ohshima K, Inoue K, Fujiwara A, et al. Let-7 microRNA family is selectively secreted into the extracellular environment by exosomes in a metastatic gastric cancer cell line. PLoS One. 2010;5:e13247.
45. Rabinowits G, Gercel-Taylor C, Day JM, et al. Exosomal micro-RNA: a diagnostic marker for lung cancer. Clin Lung Cancer. 2009;10: 42-46.
46. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35:122-128. (Pubitemid 38133932)
47. Rupp AK, Rupp C, Keller S, et al. Loss of EpCAM expression in breast cancer derived serum exosomes: role of proteolytic cleavage. Gynecol Oncol. 2011;122:437-446.
48. Taylor DD, Gercel-Taylor C. Micro-RNA signatures of tumor-derived exosomes as diagnostic biomar-kers of ovarian cancer. Gynecol Oncol. 2008;110:13-21. (Pubitemid 351853251)
49. Rosell R, Wei J, Taron M. Circulating microRNA signatures of tumor-derived exosomes for early diagnosis of non-small-cell lung cancer. Clin Lung Cancer. 2009;10:8-9.
50. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer. 2009;100:1603-1607.
51. Mitchell PJ, Welton J, Staffurth J, et al. Can urinary exosomes act as treatment response markers in prostate cancer? J Transl Med. 2009;7:4.
52. del Cacho E, Gallego M, Lee SH, et al. Induction of protective immunity against Eimeria tenella. Eimeria maxima, and Eimeria acer-vulina infections using dendritic cell-derived exosomes. Infect Immun. 2012;80:1909-1916.
53. Luketic L, Delanghe J, Sobol PT, et al. Antigen presentation by exo-somes released from peptide-pulsed dendritic cells is not suppressed by the presence of active CTL. J Immunol. 2007;179:5024-5032.
54. Escudier B, Dorval T, Chaput N, et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exo-somes: results of the first phase I clinical trial. J Transl Med. 2005;3:10.
55. Morse MA, Garst J, Osada T, et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med. 2005;3:9.
56. Yin W, Ouyang S, Li Y, et al. Immature dendritic cell-derived exosomes: a promise subcellular vaccine for autoimmunity. Inflammation. 2013;36:232-240.
57. Ohno S, Takanashi M, Sudo K, et al. Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther. 2013;21:185-191.
58. Sun D, Zhuang X, Xiang X, et al. A novel nanoparticle drug delivery system: the anti-inflammatory activity of curcumin is enhanced when encapsulated in exosomes. Mol Ther. 2010;18:1606-1614.
59. Marleau AM, Chen CS, Joyce JA, Tullis RH. Exosome removal as a therapeutic adjuvant in cancer. J Transl Med. 2012;10:134.